{"id":72256,"date":"2026-08-11T12:24:38","date_gmt":"2026-08-11T04:24:38","guid":{"rendered":"https:\/\/flcube.com\/?p=72256"},"modified":"2026-08-11T12:24:39","modified_gmt":"2026-08-11T04:24:39","slug":"hanx-biopharmaceuticals-partners-with-swiss-ai-biotech-twinedge-bioscience-to-advance-bispecific-antibody-candidate-hx009-for-dlbcl","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72256","title":{"rendered":"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3378:HKG\">HKG: 3378<\/a>)<\/strong> announced a collaboration with <strong>TwinEdge Bioscience<\/strong>, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness <strong>artificial intelligence<\/strong> to conduct translational medicine research focused on Hanx Bio&#8217;s core <strong>bispecific antibody therapeutic candidate, HX009<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-collaboration-overview\" class=\"wp-block-heading\">Collaboration Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) \u00d7 TwinEdge Bioscience (Switzerland)<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>AI\u2011driven translational medicine research collaboration<\/td><\/tr><tr><td><strong>Focus Asset<\/strong><\/td><td>HX009 \u2014 core bispecific antibody therapeutic candidate<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>TwinEdge&#8217;s proprietary AI models and computational biology tools<\/td><\/tr><tr><td><strong>Disease Focus<\/strong><\/td><td>Diffuse large B\u2011cell lymphoma (DLBCL)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>2 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-scope-of-work-ai-driven-digital-twin-development\" class=\"wp-block-heading\">Scope of Work \u2013 AI\u2011Driven &#8220;Digital Twin&#8221; Development<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Under the agreement, <strong>TwinEdge Bioscience<\/strong> will use its proprietary AI models and tools to develop personalized <strong>&#8220;Digital Twins&#8221; (or Avatars)<\/strong> based on a series of <strong>diffuse large B\u2011cell lymphoma (DLBCL) patient\u2011derived xenograft (PDX) mouse models<\/strong>. The partnership aims to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Further elucidate HX009&#8217;s mechanism of action<\/strong><\/li>\n\n\n\n<li><strong>Simulate HX009&#8217;s potential clinical performance<\/strong> in lymphoma patients<\/li>\n\n\n\n<li><strong>Explore the applicability and relevance<\/strong> of this mechanism in DLBCL<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-drug-profile-hx009\" class=\"wp-block-heading\">Drug Profile \u2013 HX009<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Molecule Type<\/strong><\/td><td>Innovative bifunctional <strong>anti\u2011PD\u20111\/SIRP\u03b1 fusion protein<\/strong><\/td><\/tr><tr><td><strong>Positioning<\/strong><\/td><td>Novel, next\u2011generation PD\u20111 therapy designed to enhance PD\u20111 function<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Synergistically binds CD8+ effector T cells within the tumor microenvironment (TIL\u2011Teff) and dual\u2011targets both <strong>PD\u20111<\/strong> and <strong>CD47<\/strong> receptors on these cells<\/td><\/tr><tr><td><strong>Effect<\/strong><\/td><td>Boosts anti\u2011tumor immunity<\/td><\/tr><tr><td><strong>Clinical Status<\/strong><\/td><td>Recently completed clinical proof\u2011of\u2011concept (POC) study for <strong>EBV\u2011positive non\u2011Hodgkin lymphoma<\/strong> (including EBV\u2011positive DLBCL)<\/td><\/tr><tr><td><strong>Next Milestone<\/strong><\/td><td>Plans to initiate pivotal clinical trials for this indication<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-impact\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AI Meets Bispecifics:<\/strong> The collaboration pairs Hanx Bio&#8217;s bispecific antibody asset with TwinEdge&#8217;s <strong>computational biology platform<\/strong>, using AI\u2011powered Digital Twins to de\u2011risk clinical development and sharpen mechanistic understanding ahead of pivotal trials.<\/li>\n\n\n\n<li><strong>Next\u2011Generation PD\u20111 Positioning:<\/strong> HX009&#8217;s dual\u2011targeting <strong>anti\u2011PD\u20111\/SIRP\u03b1<\/strong> design aims to improve on the crowded PD\u20111 inhibitor landscape by enhancing effector T\u2011cell function within the tumor microenvironment \u2014 a key differentiator in immuno\u2011oncology.<\/li>\n\n\n\n<li><strong>DLBCL Opportunity:<\/strong> DLBCL is the most common subtype of non\u2011Hodgkin lymphoma, with substantial unmet need in relapsed and hard\u2011to\u2011treat populations, including EBV\u2011positive disease.<\/li>\n\n\n\n<li><strong>POC\u2011to\u2011Pivotal Momentum:<\/strong> Having completed a clinical POC study in EBV\u2011positive NHL, Hanx Bio&#8217;s plan to move into pivotal trials gives the collaboration a near\u2011term clinical catalyst that AI modeling can help optimize.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the collaboration&#8217;s research outcomes, HX009&#8217;s clinical performance, and pivotal trial plans. Actual results may differ due to risks including translational research findings, regulatory pathways, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026070204052_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070204052_c.\"><\/object><a id=\"wp-block-file--media-6c73a38e-dbae-470a-a54f-130e27bfd395\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026070204052_c.pdf\">2026070204052_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026070204052_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6c73a38e-dbae-470a-a54f-130e27bfd395\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[99,16,2333,4503,4885],"class_list":["post-72256","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-cancer","tag-hanx-biopharmaceuticals","tag-hkg-3378","tag-twinedge-bioscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio&#039;s core bispecific antibody therapeutic candidate, HX009.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL\" \/>\n<meta property=\"og:description\" content=\"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio&#039;s core bispecific antibody therapeutic candidate, HX009.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72256\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-11T04:24:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-11T04:24:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72256#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72256\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL\",\"datePublished\":\"2026-08-11T04:24:38+00:00\",\"dateModified\":\"2026-08-11T04:24:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72256\"},\"wordCount\":461,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Cancer\",\"Hanx Biopharmaceuticals\",\"HKG: 3378\",\"TwinEdge Bioscience\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72256#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72256\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72256\",\"name\":\"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-11T04:24:38+00:00\",\"dateModified\":\"2026-08-11T04:24:39+00:00\",\"description\":\"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio's core bispecific antibody therapeutic candidate, HX009.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72256\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL - Insight, China&#039;s Pharmaceutical Industry","description":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio's core bispecific antibody therapeutic candidate, HX009.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72256","og_locale":"en_US","og_type":"article","og_title":"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL","og_description":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio's core bispecific antibody therapeutic candidate, HX009.","og_url":"https:\/\/flcube.com\/?p=72256","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-11T04:24:38+00:00","article_modified_time":"2026-08-11T04:24:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72256#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72256"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL","datePublished":"2026-08-11T04:24:38+00:00","dateModified":"2026-08-11T04:24:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72256"},"wordCount":461,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Cancer","Hanx Biopharmaceuticals","HKG: 3378","TwinEdge Bioscience"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72256#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72256","url":"https:\/\/flcube.com\/?p=72256","name":"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-11T04:24:38+00:00","dateModified":"2026-08-11T04:24:39+00:00","description":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HKG: 3378) announced a collaboration with TwinEdge Bioscience, a cutting\u2011edge Swiss biotechnology company leveraging proprietary computational biology technology. The two companies will harness artificial intelligence to conduct translational medicine research focused on Hanx Bio's core bispecific antibody therapeutic candidate, HX009.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72256"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hanx Biopharmaceuticals Partners With Swiss AI Biotech TwinEdge Bioscience to Advance Bispecific Antibody Candidate HX009 for DLBCL"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72256"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72256\/revisions"}],"predecessor-version":[{"id":72258,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72256\/revisions\/72258"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}